Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option t...
February 17 2021 - 4:05PM
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the
completion of its previously announced underwritten public offering
of 7,532,500 shares of its common stock at a price to the public of
$26.75 per share, including 982,500 shares sold pursuant to the
exercise in full of the underwriters’ option to purchase additional
shares. All of the shares were sold by Travere. Including the
option exercise, the aggregate gross proceeds from the offering
were approximately $201.5 million, before deducting the
underwriting discounts and commissions and offering expenses.
BofA Securities, Jefferies and SVB Leerink acted
as the joint book-running managers for the offering. Canaccord
Genuity acted as lead manager.
The shares of common stock described above were
offered by Travere pursuant to a shelf registration statement filed
by Travere with the Securities and Exchange Commission (SEC) that
became automatically effective on September 4, 2018. A final
prospectus supplement and accompanying prospectus related to the
offering have been filed with the SEC and are available on the
SEC’s website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus related to
this offering may be obtained from BofA Securities, Attention
Prospectus Department, 200 North College Street, 3rd Floor,
Charlotte, NC 28255 or by email at dg.prospectus_requests@bofa.com;
from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by
email at Prospectus_Department@Jefferies.com; or from SVB Leerink,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110 or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Travere Therapeutics
At Travere Therapeutics we are in rare for life.
We are a biopharmaceutical company that comes together every day to
help patients, families and caregivers of all backgrounds as they
navigate life with a rare disease. On this path, we know the need
for treatment options is urgent – that is why our global team works
with the rare disease community to identify, develop and deliver
life-changing therapies. In pursuit of this mission, we
continuously seek to understand the diverse perspectives of rare
patients and to courageously forge new paths to make a difference
in their lives and provide hope – today and tomorrow. For more
information, visit travere.com.
Contact:Chris Cline, CFASenior Vice President,
Investor Relations & Corporate
Communications888-969-7879IR@travere.com
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Sep 2023 to Sep 2024